Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  SANOFI    SAN   FR0000120578

SANOFI (SAN)

2541
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo SANOFI
Engages in the research, production and distribution of pharmaceutical products

Sanofi engages in the research, production and distribution of pharmaceutical products.

The company focuses on the following seven platforms in healthcare field: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.

It operates through the following segments: Pharmaceuticals, Human Vaccines and Animal Health.

The Pharmaceuticals segment includes research, development, production and sales activities relating to pharmaceutical products, including prescription, consumer health care, and generic products.

This segment also includes equity affiliates and joint ventures with pharmaceutical business activities.

The Human Vaccines segment includes research, development, production and marketing of vaccines.

The Animal Health segment comprises the research, development, production and marketing activities for Merial, which offers a range of medicines and vaccines for a wide variety of animal species.

The company was founded in 1994 and is headquartered in Paris, France.

Number of employees : 112 128 persons.
Sales per Businesses
20122013Delta
EUR (in Million)%EUR (in Million)%
Pharmaceuticals28,87182.6%27,25082.7% -5.95%
Human Vaccines3,89711.2%3,71611.3% -4.87%
Animal Health2,1796.2%1,9856% -9.77%
Sales per Regions
20122013Delta
EUR (in Million)%EUR (in Million)%
Rest of the World12,45135.6%11,44134.7% -8.83%
United States10,87331.1%10,43331.7% -4.22%
Europe (Excluding France)8,21023.5%7,93324.1% -3.49%
France2,8468.1%2,5717.8% -10.7%
North America567.001.6%573.001.7% +1.05%
Managers
NameAgeSinceTitle
Serge Weinberg632009Chairman & Chief Executive Officer
Jérôme Contamine572009Chief Financial Officer & Executive Vice President
Elias E. Zerhouni, MD632011President-Global Research & Development
Bruno Ménard-2011Chief Information Officer
Ji Zhang, PhD-2003Head-Research & Development Scientific Platforms
Paul Chew, PhD-2013Chief Medical Officer & Senior Vice President
Igor Landau, MBA702004Director
Robert Castaigne, PhD682000Independent Director
Jean-René Fourtou752004Independent Director
Claudie Haigneré MD, PhD572008Independent Director
Shareholders
NameShares%
L'Oréal SA 118,227,3078.93%
Norges Bank Investment Management 28,497,0582.15%
Dodge & Cox, Inc. 21,054,6651.59%
Amundi SA (Investment Management) 17,805,2991.35%
Plan d'Epargne Entreprise Sanofi Synthelabo 17,366,8921.31%
Natixis Asset Management SA 16,569,4891.25%
The Vanguard Group, Inc. 13,377,3701.01%
BlackRock Fund Advisors 10,460,1370.79%
Lyxor International Asset Management SAS 10,183,5610.77%
FIL Investments International 10,180,4690.77%
Holdings
NameShares%Valuation
Regeneron Pharmaceuticals Inc (REGN) 22,657,68522.9%8,168,548,596 USD
Aventis Pharma Limited (AVPH) 13,909,58760.4%741,210,316 USD
Sanofi India Ltd (SANOFI) 13,909,58760.4%741,210,316 USD
SANOFI (SAN) 3,632,5990.27%410,980,154 USD
Zentiva SA (ROSCD) 312,341,64974.9%116,253,562 USD
Nichi-iko Pharmaceutical Co., Ltd. (4541) 2,846,0004.69%45,999,898 USD
GENFIT (GNFT) 355,2991.52%18,927,222 USD
Immune Design Corp 917,4295.44%16,201,796 USD
GlycoMimetics Inc (GLYC) 1,193,6256.32%8,283,758 USD
Proteome Sciences plc (PRM) 56,0000.026%32,455 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Pharmaceuticals - NEC
Advertisement
Surperformance© rating
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
PER
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
More Ratings
Sector Pharmaceuticals
Growth (Revenue) Profitability
JOHNSON & JOHNSON
NOVARTIS AG
ROCHE HOLDING LTD..
PFIZER INC.
MERCK & CO., INC.
SANOFI
BAYER AG
GLAXOSMITHKLINE P..
BRISTOL-MYERS SQU..
NOVO NORDISK A/S
ELI LILLY AND CO
ACTAVIS PLC
ABBOTT LABORATORI..
ALLERGAN, INC.
TEVA PHARMACEUTIC..
VALEANT PHARMACEU..
SHIRE PLC
REGENERON PHARMAC..
ASTELLAS PHARMA I..
TAKEDA PHARMACEUT..
Sector Pharmaceuticals
Company contact information
54 rue la Boétie
FR-75008 Paris
France

Phone : +33 (0)1 53 77 40 00
Fax : +33 (0)1 53 77 44 63
Internet : http://www.sanofi.com
Markets and indexes
- PEA / SRD eligible : YES / YES
- NYSE Euronext Paris
- Compartiment A
- CAC 40 / CAC All Shares, CAC All-Tradable, CAC Large 60, Euronext 100, EuroStoxx 50, FTSE Eurotop 100, Stoxx Europe 50, Stoxx France 50, Stoxx Global 200
Stock Exchange Codes
- ISIN Code :  FR0000120578
- Bloomberg Code :  SAN:FP
- Reuters Code :  SASY.PA
- Datastream Code :  F:SQ@F
© 2014 Factset    © 2014 Cofisem   
Dynamic quotes  
ON
| OFF